Advertisement
Screener

Denali Therapeutics Inc. (DNLI) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

2.4 / 5 stars · 37/77 Roast Me

Denali Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent

Denali Therapeutics Inc. (DNLI) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-06

  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.29M.
  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.36M, a 8123.53% decline year-over-year.
  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$419.00K.
  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $162.00K, a 98.02% decline year-over-year.
  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$1.34M, a 197.17% decline from fiscal 2024.
  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $1.38M, a 81.71% decline from fiscal 2023.
  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $7.53M.
  • Denali Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$4.39M.
Period endOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 monthOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 monthOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 monthOther Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month
2026-06-30-$1.29M
10-Q · filed 2026-08-06
-$2.65M
10-Q · filed 2026-08-06
-$3.07M
derived: sum of 3 quarters · filed 2026-08-06
-$2.91M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$1.36M
10-Q · filed 2026-05-07
-$1.78M
derived: sum of 2 quarters · filed 2026-05-07
-$1.62M
derived: sum of 3 quarters · filed 2026-05-07
-$2.72M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$419.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$257.00K
derived: sum of 2 quarters · filed 2026-02-26
-$1.35M
derived: sum of 3 quarters · filed 2026-08-06
-$1.34M
10-K · filed 2026-02-26
2025-09-30$162.00K
10-Q · filed 2025-11-06
-$936.00K
derived: sum of 2 quarters · filed 2026-08-06
-$919.00K
10-Q · filed 2025-11-06
-$4.43M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$1.10M
10-Q · filed 2026-08-06
-$1.08M
10-Q · filed 2026-08-06
-$4.59M
derived: sum of 3 quarters · filed 2026-08-06
$3.60M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$17.00K
10-Q · filed 2026-05-07
-$3.49M
derived: sum of 2 quarters · filed 2026-05-07
$4.70M
derived: sum of 3 quarters · filed 2026-05-07
$3.33M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$3.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$4.68M
derived: sum of 2 quarters · filed 2026-02-26
$3.32M
derived: sum of 3 quarters · filed 2026-02-26
$1.38M
10-K · filed 2026-02-26
2024-09-30$8.19M
10-Q · filed 2025-11-06
$6.83M
derived: sum of 2 quarters · filed 2025-11-06
$4.89M
10-Q · filed 2025-11-06
$6.18M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$1.36M
10-Q · filed 2025-08-11
-$3.30M
10-Q · filed 2025-08-11
-$2.01M
derived: sum of 3 quarters · filed 2026-02-26
-$1.22M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$1.94M
10-Q · filed 2025-05-06
-$645.00K
derived: sum of 2 quarters · filed 2026-02-26
$145.00K
derived: sum of 3 quarters · filed 2026-02-26
$1.22M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$1.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$2.08M
derived: sum of 2 quarters · filed 2026-02-26
$3.16M
derived: sum of 3 quarters · filed 2026-02-26
$7.53M
10-K · filed 2026-02-26
2023-09-30$790.00K
10-Q · filed 2024-11-06
$1.87M
derived: sum of 2 quarters · filed 2024-11-06
$6.24M
10-Q · filed 2024-11-06
$11.20M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$1.08M
10-Q · filed 2024-08-01
$5.45M
10-Q · filed 2024-08-01
$10.41M
derived: sum of 3 quarters · filed 2025-02-27
$10.83M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$4.37M
10-Q · filed 2024-05-07
$9.34M
derived: sum of 2 quarters · filed 2025-02-27
$9.76M
derived: sum of 3 quarters · filed 2025-02-27
$6.73M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$4.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$5.39M
derived: sum of 2 quarters · filed 2025-02-27
$2.37M
derived: sum of 3 quarters · filed 2025-02-27
-$4.39M
10-K · filed 2025-02-27
2022-09-30$421.00K
10-Q · filed 2023-11-07
-$2.60M
derived: sum of 2 quarters · filed 2023-11-07
-$9.35M
10-Q · filed 2023-11-07
-$11.33M
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30-$3.02M
10-Q · filed 2023-08-08
-$9.78M
10-Q · filed 2023-08-08
-$11.75M
derived: sum of 3 quarters · filed 2024-02-28
-$11.91M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31-$6.75M
10-Q · filed 2023-05-08
-$8.73M
derived: sum of 2 quarters · filed 2024-02-28
-$8.88M
derived: sum of 3 quarters · filed 2024-02-28
-$9.02M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31-$1.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
-$2.13M
derived: sum of 2 quarters · filed 2024-02-28
-$2.27M
derived: sum of 3 quarters · filed 2024-02-28
-$2.25M
10-K · filed 2024-02-28
2021-09-30-$153.00K
10-Q · filed 2022-11-03
-$289.00K
derived: sum of 2 quarters · filed 2022-11-03
-$276.00K
10-Q · filed 2022-11-03
-$532.00K
derived: sum of 4 quarters · filed 2023-02-27
2021-06-30-$136.00K
10-Q · filed 2022-08-08
-$123.00K
10-Q · filed 2022-08-08
-$379.00K
derived: sum of 3 quarters · filed 2023-02-27
-$919.00K
derived: sum of 4 quarters · filed 2023-02-27
2021-03-31$13.00K
10-Q · filed 2022-05-05
-$243.00K
derived: sum of 2 quarters · filed 2023-02-27
-$783.00K
derived: sum of 3 quarters · filed 2023-02-27
-$1.07M
derived: sum of 4 quarters · filed 2023-02-27
2020-12-31-$256.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
-$796.00K
derived: sum of 2 quarters · filed 2023-02-27
-$1.08M
derived: sum of 3 quarters · filed 2023-02-27
-$595.00K
10-K · filed 2023-02-27
2020-09-30-$540.00K
10-Q · filed 2021-11-04
-$824.00K
derived: sum of 2 quarters · filed 2021-11-04
-$339.00K
10-Q · filed 2021-11-04
-$551.00K
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30-$284.00K
10-Q · filed 2021-08-04
$201.00K
10-Q · filed 2021-08-04
-$11.00K
derived: sum of 3 quarters · filed 2022-02-28
-$328.00K
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$485.00K
10-Q · filed 2021-05-05
$273.00K
derived: sum of 2 quarters · filed 2022-02-28
-$44.00K
derived: sum of 3 quarters · filed 2022-02-28
$503.00K
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31-$212.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
-$529.00K
derived: sum of 2 quarters · filed 2022-02-28
$18.00K
derived: sum of 3 quarters · filed 2022-02-28
$999.00K
10-K · filed 2022-02-28
2019-09-30-$317.00K
10-Q · filed 2020-11-05
$230.00K
derived: sum of 2 quarters · filed 2020-11-05
$1.21M
10-Q · filed 2020-11-05
$1.98M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30$547.00K
10-Q · filed 2020-08-07
$1.53M
10-Q · filed 2020-08-07
$2.29M
derived: sum of 3 quarters · filed 2021-02-26
$2.37M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31$981.00K
10-Q · filed 2020-05-07
$1.75M
derived: sum of 2 quarters · filed 2021-02-26
$1.82M
derived: sum of 3 quarters · filed 2021-02-26
$1.62M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31$767.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
$844.00K
derived: sum of 2 quarters · filed 2021-02-26
$638.00K
derived: sum of 3 quarters · filed 2021-02-26
-$281.00K
10-K · filed 2021-02-26
2018-09-30$77.00K
10-Q · filed 2019-11-06
-$129.00K
derived: sum of 2 quarters · filed 2019-11-06
-$1.05M
10-Q · filed 2019-11-06
2018-06-30-$206.00K
10-Q · filed 2019-08-06
-$1.13M
10-Q · filed 2019-08-06
2018-03-31-$919.00K
10-Q · filed 2019-05-08
2017-12-31$5.00K
10-K · filed 2020-02-27
2016-12-31-$373.00K
10-K · filed 2019-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43